Digital Toolkit for the Maternal RSV Vaccine
The Society for Maternal-Fetal Medicine (SMFM) has developed a digital toolkit on the maternal respiratory syncytial virus (RSV) vaccine. This toolkit includes resources designed to education obstetric care clinicians, pharmacists, patients and families about how to protect infants against severe RSV disease.
RSV is a leading cause of lower respiratory tract illness globally in children under 5 years and is the leading cause of infant hospitalization in the US. To prevent severe morbidity and mortality in infants, pregnant people can receive the maternal RSV vaccine from 32 through 36 weeks of gestation using seasonal administration. Infants born to people who received the maternal RSV vaccine during a prior pregnancy or declined this vaccine should receive nirsevimab, a monoclonal antibody. Abrysvo by Pfizer is the only approved RSV vaccine for use in pregnancy.
We encourage you to browse these resources and share them across your professional and member networks to help increase knowledge about the maternal RSV vaccine. Available resources include clinician and patient fact sheets, podcasts, animated patient education videos in English and Spanish, and a series of short videos tailored to both professional and public audiences.
- Abrysvo (Pfizer's RSV Vaccine) Refer to this fact sheet for quick facts on the maternal RSV vaccine, Abrysvo by Pfizer, as well as tips for vaccine referral, access and cost.
- Maternal RSV Vaccination 101 In this episode of the SMFM Podcast, Dr. Marwan Ma’ayeh discusses maternal RSV vaccination with Dr. Sarah Boudova, an expert in infectious diseases and a third-year maternal-fetal medicine fellow. They dive into the Abrysvo vaccine and explain its importance for protecting newborns from RSV-related respiratory illnesses. Dr. Boudova provides essential insights into the vaccine's components, its unique role during pregnancy, timing considerations, and co-administration with other vaccines. They also touch on current recommendations from leading health organizations and outline practical advice for healthcare providers on storing and administering the vaccine. Listen to learn how maternal RSV vaccination can safeguard infant health during the RSV season and look out for the upcoming episode, which will cover patient education, access, and cost.
- Maternal RSV Vaccination 102 In this episode of the SMFM podcast, Dr. Kecia Gaither and Dr. Neil Silverman discuss maternal RSV vaccination and the Pfizer Abrysvo vaccine. Learn about the latest updates for the 2024-2025 respiratory season, how to counsel patients effectively, and strategies to ensure vaccine access. The conversation also covers addressing vaccine hesitancy, navigating barriers like cost and availability, and comparing maternal vaccination with neonatal immunization options to protect infants from severe RSV infection.
-
RSV Immunization Decision Guide in Pregnancy Refer to this decision guide to help determine if you should receive the maternal RSV vaccine during pregnancy or if your baby should receive the nirsevimab immunization to protect your baby against severe disease.
Hear from Dr. Stephanie Ros, a maternal-fetal medicine subspecialist, what she shares with her patients when recommending the maternal RSV vaccine.
What Patients Need to Know: An MFM Perspective (English) (Español muy pronto)
Getting the maternal RSV vaccine during pregnancy can help protect your baby from severe disease. Watch this video on RSV vaccine safety to learn more.
SMFM Video on Maternal RSV Vaccine Safety (English) (Español)
The maternal RSV vaccine is administered from 32 through 36 weeks of pregnancy. Watch this video on RSV vaccine timing to learn more.
SMFM Video on Maternal RSV Vaccine Timing (English) (Español)
Last Updated January 7, 2025